Loading…
← CockpitCompetitor Analysis › 301301.SZ Yili Chuanning Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

Yili Chuanning Biotechnology Co., Ltd. Class A301301.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese biotechnology company; specific product lines not confirmed from available knowledge.

Momentum neutral 53
Mkt cap
$2.49B
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$14.9M
20-day average traded
Fwd P/E
27.6×
forward earnings
ROIC−WACC
+3.5 pp
WACC 6.2%
Hurdle
-1 pp
Req g minus delivered
Next earnings
139 days
6 Apr 2027
Close · CNYCN¥7.42
1D-1.2%
1W-6.2%
1M-6.9%
3M-17.2%
6M-23.9%
YTD-26.8%
1Y-35.8%
ATR %3.2%
52w lowhigh42.5% off high

What Yili Chuanning Biotechnology does

Chinese biotechnology company; specific product lines not confirmed from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Biotechnology

Moat: none

Headquarters: China · Employees: 3,126

Yili Chuanning Biotechnology at a glance

Size Yili Chuanning Biotechnology (301301.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.49B, the 958th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.42 on 18 Nov 2026.

Performance Over six months the shares fell 23.9%, against -8.4% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue fell 14.2% over the last twelve months (peer median +4.2%); the operating margin is 15.6% (peer median 9.1%).

Valuation It trades at 27.6× forward earnings against a peer median of 26.2× (7th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.5 points above its cost of capital (6.2% WACC).

Next results Next results expected around 6 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 90301301.SZ 77
Six months, rebased to 100: Yili Chuanning Biotechnology against the median of its 20 peers (local-currency closes).

Yili Chuanning Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.06BCN¥4.58BCN¥5.71BCN¥4.78BCN¥3.79B
Revenue growth—-20%+19%+26%—
Gross profitCN¥1.35BCN¥1.27BCN¥2.00BCN¥1.45BCN¥876M
EBITDAn/aCN¥1.56BCN¥2.30BCN¥1.74BCN¥1.22B
Net incomeCN¥490MCN¥769MCN¥1.40BCN¥941MCN¥412M
Free cash flowCN¥713MCN¥452MCN¥1.75BCN¥947MCN¥644M
Capital expenditureCN¥87.5MCN¥97.2MCN¥42.6MCN¥345MCN¥47.2M
Total debtCN¥1.24BCN¥1.39BCN¥1.57BCN¥2.23BCN¥3.37B

Quarterly statements and history in the cockpit →

Yili Chuanning Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%ALMIDYAPBH369621626005180013NAMS000250PRGOBIOA-BRGC300199301080300558APLLTD600267600380301301.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Yili Chuanning Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×ALMPBH369621620013PRGOBIOA-B300199301080300558600267301301.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Yili Chuanning Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%ALMPBH36960013PRGOBIOA-B300199301080300558603858600267600380301301.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Yili Chuanning Biotechnology is the large dot.

Yili Chuanning Biotechnology competitors and peer comparison

How Yili Chuanning Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Yili Chuanning Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure301301.SZPeer medianRank in peer set
1-month return-6.9%-3.1%9th lowest of 21
6-month return-23.9%-8.4%5th lowest of 21
Distance from 52-week high-42.5%-27.2%7th lowest of 21
Revenue growth (TTM)-14.2%+4.2%4th lowest of 20
Operating margin15.6%9.1%6th highest of 19
Forward P/E27.6×26.2×7th most expensive of 15
Growth the price implies (Req g, 7 yrs)3.4%18.7%6th least demanding of 15
Growth delivered (Del g)+4.8%+6.3%7th lowest of 15
Hurdle (Req g minus delivered)-1.3 pp+6.3 pp4th least demanding of 15
ROIC minus cost of capital+3.5 pp-2.2 pp4th highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%

Questions

Which companies are Yili Chuanning Biotechnology's closest peers?
The cockpit's peer set: Almirall (ALM.MC), IDEAYA Biosciences (IDYA), Prestige Consumer Healthcare (PBH), InSilico Medicine Cayman TopCo (3696.HK), Keymed Biosciences (2162.HK), Kangmei Pharmaceutical (600518.SS), HUTCHMED (China) (0013.HK), NewAmsterdam Pharma (NAMS).
Is Yili Chuanning Biotechnology expensive compared with its peers?
On forward p/e it trades at 27.6× against a peer median of 26.2×, 7th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Yili Chuanning Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -23.9% against -8.4% for the median peer; over one year -35.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.